Cancer is one of the main public health problems in the world. Systemic therapies such as
chemotherapy and more recently target therapies as well as immunotherapy have improved …

Immune evasion is a hallmark of cancer, enabling tumors to survive contact with the host
immune system and evade the cycle of immune recognition and destruction. Here, we …

Summary Interferon-γ (IFN-γ) signaling mediates host responses to infection, inflammation
and anti-tumor immunity. Mutations in the IFN-γ signaling pathway cause immunological …

Summary KRAS G12C inhibitors (adagrasib and sotorasib) have shown clinical promise in
targeting KRAS G12C-mutated lung cancers; however, most patients eventually develop …

Deregulated inflammation is a critical feature driving the progression of tumors harboring
mutations in the liver kinase B1 (LKB1), yet the mechanisms linking LKB1 mutations to …

Immune checkpoint inhibitor (ICI) therapies, including the programmed cell death protein 1
(PD-1) axis blockade, are considered a major oncological breakthrough of the early twenty …

Purpose Immune checkpoint inhibitors are associated with clinical benefit in lung cancer.
However, response patterns to immunotherapy, including pseudoprogression and …

Understanding of the functional states and clonal dynamics of T cells after immune
checkpoint blockade (ICB) is valuable for improving these therapeutic strategies. Here we …

Viral mimicry driven by endogenous double-stranded RNA (dsRNA) stimulates innate and
adaptive immune responses. However, the mechanisms that regulate dsRNA-forming …

SUMMARY KRASG12C inhibitors (adagrasib and sotorasib) have shown clinical promise in
targeting KRAS G12C-mutated lung cancers; however, most patients eventually develop …